Peptide · Fact sheet

Exenatide

Also known as Byetta · Bydureon · exendin-4

Exenatide has FDA-approved diabetes products, including immediate-release generic products listed as prescription. Some older branded products are discontinued. It is not approved for Parkinson disease; the larger Phase 3 trial did not confirm earlier benefit.

FDA approved for specific usesStrong human evidence for approved uses

What is Exenatide?

Exenatide is a peptide GLP-1 receptor agonist based on exendin-4, a peptide first identified in Gila monster saliva.

Its glucose-lowering approval and its experimental neurodegeneration hypothesis are separate evidence categories.

Benefits & claims

An earlier randomized Parkinson trial reported a persistent motor-score difference after a washout period, raising disease-modification interest.

The subsequent larger Phase 3 study did not confirm benefit, showing why replication outweighs a mechanism or single positive trial.

What the evidence supports

  • Approved diabetes benefits are established within labeled use.
  • An earlier Parkinson trial generated a motor signal, but the larger Phase 3 trial found no meaningful benefit on the primary motor endpoint.
Research areas
  • Type 2 diabetes
  • Parkinson disease progression
  • Motor function
  • GLP-1 neurobiology
  • Parkinson disease and neuroprotection research

Dosage & frequency

Product-specific label information

Current generic immediate-release exenatide has a twice-daily adult diabetes regimen. The cited AstraZeneca Byetta and Bydureon BCise products are discontinued; their historical schedules differ.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Byetta dosing cannot be transferred to once-weekly extended-release exenatide.

Interactions & precautions

  • The label warns about increased hypoglycemia with insulin or insulin secretagogues and delayed absorption of oral medicines.

What is still unresolved

  • Exenatide is not an approved Parkinson disease treatment.

Side effects & risks

  • The diabetes labeling describes pancreatitis, kidney injury, severe gastrointestinal disease, hypersensitivity, gallbladder disease, and rare immune-mediated thrombocytopenia among important risks.
  • Hypoglycemia risk can rise with certain other diabetes medicines.
  • Parkinson trials add tolerability demands without an established neurologic benefit.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Evidence is strong for labeled diabetes uses. For Parkinson disease, the best current evidence is a negative multicenter Phase 3 trial that outweighs the earlier small positive signal.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Better glucose readings with persistent stomach discomfort

An anonymous Bydureon reviewer described lower glucose and A1c readings with reduced cravings, but persistent bloating, heartburn and nausea that made treatment difficult to tolerate.

Reported use in this account

Product
Bydureon, as named in the August 2014 account
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; type not stated
Duration
Four weeks of reported glucose/A1c follow-up

This selected August 2014 review is unverified and does not estimate benefit or symptom frequency. Extended-release Bydureon differs from Byetta.

Read the original account
Positive account · personal report

Weight loss, fewer cravings and more energy

Another Bydureon reviewer described weight loss, lower glucose readings, less interest in sweets and more energy while also taking metformin.

Reported use in this account

Product
Bydureon, as named in the March 2014 account
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; type not stated
Duration
Not specified clearly

Other exposures described: Metformin, reported at 500 mg twice daily

This selected March 2014 review includes concurrent metformin and dietary changes; it cannot isolate exenatide or replace trial results.

Read the original account
Mixed account · personal report

Headache relief with digestive symptoms

A person prescribed extended-release Bydureon for intracranial hypertension described fewer headaches and pressure-associated symptoms, alongside constipation and nausea. Later replies reported earlier fullness without weight loss. A feared thyroid problem was subsequently attributed by their doctor to allergies after normal testing.

Reported use in this account

Product
Extended-release Bydureon prescribed off label for intracranial hypertension
Amount
Not specified clearly
Frequency
Weekly
Route
Injection; type not stated
Duration
One week in the initial post

Other exposures described: An unnamed medicine associated with weight gain was added later

This is one off-label account, with PCOS, insulin resistance, diet changes and another medicine associated with weight gain. It does not verify pressure reduction, thyroid injury or an approved use for intracranial hypertension.

Read the original account

Approval status

FDA lists generic immediate-release exenatide products under ANDA206697 as prescription. AstraZeneca Byetta under NDA021773 and Bydureon BCise under NDA209210 are listed as discontinued. Approval and marketing status are product-specific; no exenatide product is approved for Parkinson disease, cognition, or neuroprotection.

Approved uses

  • Improving glycemic control in adults with type 2 diabetes under product-specific FDA labeling

FDA-approved diabetes products; marketing status varies

FDA lists generic immediate-release exenatide as prescription while the cited AstraZeneca Byetta and Bydureon BCise presentations are discontinued. Product-specific diabetes approvals do not establish an approved Parkinson use.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether another GLP-1 molecule can produce a reproducible Parkinson benefit
  • Which pharmacologic or trial-design differences explain conflicting results
  • Whether any biomarker identifies a neurologic responder subgroup
  • Long-term brain effects outside diabetes

Summary

Exenatide has established diabetes evidence; marketing status differs by product. Its larger Phase 3 trial did not confirm the earlier Parkinson benefit.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA Drugs@FDA: generic immediate-release exenatide

    Approved generic product records with Prescription marketing status; distinguishes ingredient approval from discontinued branded presentations.

  2. fdaFDA Drugs@FDA dataset: Byetta product status

    FDA product records list Byetta products as discontinued; this is distinct from withdrawal for safety or effectiveness.

  3. fdaFDA Drugs@FDA dataset: Bydureon BCise product status

    FDA product record lists Bydureon BCise as discontinued; historical labeling is retained for context.

  4. fdaFDA prescribing information: Byetta

    Historical diabetes indication, warnings, adverse reactions, and product-specific evidence.

  5. pubmedEarlier randomized exenatide Parkinson trial

    Small controlled study that generated the disease-modification hypothesis.

  6. pubmedNegative Phase 3 exenatide Parkinson trial

    Larger multicenter trial finding no benefit on the primary motor endpoint.

  7. nihBydureon BCise prescribing information

    Primary source for the practical reference information.

  8. nihGeneric immediate-release exenatide current prescribing information

    Primary source for the practical reference information.

  9. fdaFDA Drugs@FDA dataset: generic exenatide product status

    Current prescription generic product records distinguish ingredient availability from discontinued branded presentations.

How we assess sources · Suggest a correction